Genmab: Positive 2025 Outlook, Johnson & Johnson's Decision Coming Soon
Genmab's Q4 2024 results impress with $897.4M revenue and 29% growth. GMAB's balance sheet is strong with nearly $3 billion ...
Leerink Partnrs Estimates Genmab A/S Q3 Earnings
Research analysts at Leerink Partnrs issued their Q3 2025 EPS estimates for shares of Genmab A/S in a report issued on Thursday, February 13th. Leerink Partnrs analyst J. Chang forecasts that the ...
Genmab A/S (NASDAQ:GMAB) Upgraded at Leerink Partnrs
Leerink Partnrs upgraded shares of Genmab A/S (NASDAQ:GMAB – Free Report) from a hold rating to a strong-buy rating in a ...
Japan approves Genmab’s EPKINLY for R/R follicular lymphoma treatment
Genmab (GMAB) announced that the Japan Ministry of Health, Labour and Welfare has approved EPKINLY or epcoritamab, for the treatment of ...
Genmab (GMAB) Gets a Hold from Morgan Stanley
Morgan Stanley analyst Vikram Purohit maintained a Hold rating on Genmab (GMAB – Research Report) today and set a price target of $31.00. The ...
Harding Loevner International Equity ADR Q4 2024 Report
Harding Loevner International Equity ADR composite fell 7.9%, gross, behind the 7.5% decline of the MSCI ACWI ex US Index.
pharmaphorum3d
Jan van de Winkel: Building Europe’s biotech powerhouse at Genmab
The last ten years has seen Denmark’s Genmab become one of biotech’s big ... from financially precarious position following the stock market crash in the late noughties, to the darling of ...
Benzinga.com2d
Today's Analyst Stock Ratings | Upgrades, Downgrades
Jones Trading Maintains Buy on BrightSpire Capital, Maintains $7.25 Price Target Analyst ratings measure the expected performance of a stock during a given time period. Analysts and brokerage ...
pharmaphorum2d
J&J rumoured to be sizing up $12bn Genmab acquisition
Speculation is mounting that Johnson & Johnson could buy its Danish R&D partner Genmab, a pairing that has created the successful blood cancer drug Darzalex. J&J this year bought Swiss biotech ...